• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Government of the Principality of Monaco supports DNDi to increase access to improved treatment for children with HIV

Home > Press releases

Government of the Principality of Monaco supports DNDi to increase access to improved treatment for children with HIV

Dr Monique Wasunna, Eastern Africa Regional Director, DNDi; Carole Lanteri, Ambassador and Permanent Representative at UNOG for the Government of the Principality of Monaco; Dr Bernard Pécoul, Executive Director, DNDi
Monaco / Geneva — 8 Apr 2022

From left to right: Dr Monique Wasunna, Eastern Africa Regional Director, DNDi; Carole Lanteri, Ambassador and Permanent Representative at UNOG for the Government of the Principality of Monaco; Dr Bernard Pécoul, Executive Director, DNDi

  • English
    • English
    • Français

The Government of the Principality of Monaco and the Drugs for Neglected Diseases initiative (DNDi) are pleased to announce their partnership to help put an end to the neglect of children living with HIV.

With a commitment of EUR 300,000 over three years (2022-2024), the Monegasque Cooperation for Development will support DNDi’s efforts to improve access to optimal HIV treatments for young children.

‘We are very pleased to count on the support of the Government of the Principality of Monaco,’ said Dr Bernard Pécoul, Executive Director of DNDi. ‘For too long, children living with HIV have been neglected, particularly those living in low-resource settings. Today, we are witnessing a revolution in the diagnosis and treatment of paediatric HIV. It is now our responsibility to ensure that children living with HIV have access to these game-changing diagnostics and treatments.’

Despite a huge increase in the number of adults accessing life-saving HIV treatment, children are still being left behind. Almost 800,000 kids living with HIV – the majority in sub-Saharan Africa – are not on treatment. This represents close to 50% of children living with HIV worldwide. Without treatment, half of all children born with HIV will die by the age of two.

South Africa has the largest HIV burden globally: with 310,000 children living with HIV, under half (47%) receive anti-retroviral treatment (ART). In Senegal, only a third of the 4,000 children living with HIV have access to ART.

This Monaco-funded project will work to address barriers to HIV treatment in these two countries. In South Africa, DNDi will support the registration of an improved taste-masked combination HIV treatment that is a marked improvement over the bitter-tasting and hard-to-administer options that are currently available in the country. In Senegal, the project will help strengthen local capacity to diagnose and treat HIV in children through training of healthcare personnel and local communities.

‘The Government of the Principality of Monaco is delighted with this partnership with DNDi to help improve access to treatment for children with HIV in two of its partner countries, South Africa and Senegal. This health partnership is in line with the priorities of the Monegasque Cooperation, with the most vulnerable as its main focus. We hope that advances in diagnosis and treatment for HIV will soon benefit the greatest number of children, so that no one is left behind’, said Bénédicte Schutz, Monaco’s Special Representative for International Cooperation.

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in low- and middle-income countries. Since its inception in 2003, DNDi has delivered nine new treatments, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

About the Government of the Principality of Monaco

The Government of Monaco’s international development policy, which has made fight against poverty its priority, support around 150 projects each year in 11 countries, mainly LDCs (Madagascar, Mali, Burkina Faso, Niger, Mauritania, Senegal and Burundi). The aid focuses on four key areas of intervention to develop human capital – health, fod security, education & child protection, access to decent work – and targets the most vulnerable people (women, children, refugees, people with disabilities) as a priority. cooperation-monaco.gouv.mc

Media contacts 

DNDi – Frédéric Ojardias
fojardias@dndi.org
+41 79 431 62 16  

Government of the Principality of Monaco – Julien Siri
jsiri@gouv.mc
+377 98 98 49 76

Photo credit: Ariane Mawaffo-DNDi

Funding Children Paediatric HIV

Read, watch, share

Loading...
News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License